Fixing Drug Pricing? Congress Enacts Generic Inflation Rebate And Turns Up Heat On FDA
This article was originally published in RPM Report
Executive Summary
Amid a storm of controversy about “re-pricing” of older brands, the US Congress has reacted in two seemingly contradictory ways. First, new legislation creates what amounts to a tax on generic drug companies who raise prices. At the same time, legislators are eager to press FDA to move faster on generic drug approvals to assure competition for high priced brands.